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1. Introduction 
The squamous cell carcinoma of the skin (SCCS) is one of the most common cancers around 
the world.(Ries, Melbert et al. 2007; 2008) It affects mostly the sun exposed areas of people 
with fair skin. The majority of cases are easily treatable by simple excision or radiotherapy 
with a good chance of achieving cure. Despite this, the aging population process associated 
to chronic ultraviolet radiation (U.V.) exposition is raising the SCCS incidence and 
consequently the number of patients with advanced tumors.(Staples, Elwood et al. 2006) 
This is a devastating presentation of the disease, where the lack of information occurs and 
even the professionals in the field are a few. Local disease progression, local and regional 
recurrence, lymph node or distant metastases are the focus of this review chapter. The 
characteristics of the tumors arising in the trunk and extremities are different from those in 
the head and neck, and they are described and discussed separately. 
2. Advanced squamous cell carcinoma of the skin of the trunk and 
extremities  
2.1 Definition 
We consider as patients with advanced squamous cell carcinoma of the skin of the trunk 
and extremities, those with T3/T4 (tumor invading deep structures/axial esqueleton) or 
N1/2/3 (regional lymph node metastasis) tumors according the 7th UICC TNM 
classification(Sobin and Compton). Tumors arising from genital or anus are not 
considered. 
2.2 Epidemiology, clinical presentation, diagnostic methods and defining a risk 
population 
There are some clinical conditions associated to locally advanced disease. The patients are 
typically old, with risk conditions to skin carcinomas (chronic U.V. exposition and fair skin) 
and may have other local disease as burn scars, chronic skin ulcer and systemic pathologies 
related to immune system suppression (organ transplant receptors, hematopoietic 
disorders)(Cherpelis, Marcusen et al. 2002; Trakatelli, Ulrich et al. 2007). Low economic and 
educational status or difficult access to the health system may also play a role to the 
presentation of advanced cases, but not confirmed in studies. 
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The usual presentation is a patient with a long story of a “chronic ulcer” with many 
previous local treatments. Some present with pathological bone fractures or lymph node 
metastasis. (de Lima Vazquez, Sachetto et al. 2008) 
 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Tumor ≤ 2 cm in greatest dimension with 2 high-risk features* 
T2 Tumor > 2 cm in greatest dimension with or without one additional high-risk feature,* 
or any size with ≥ 2 high-risk features* 
T3 Tumor with invasion of maxilla, mandible, orbit, or temporal bone 
T4 Tumor with invasion of skeleton (axial or appendicular) or perineural invasion of 
skull base 
*High-risk features include depth (> 2-mm thickness; Clark level ≥ IV ); perineural invasion; location 
(primary site ear; primary site nonglabrous lip); and differentiation (poorly differentiated or 
undifferentiated). 
Table 1. Definition of cutaneous squamous cell carcinoma tumor (T) staging system in 7th 
edition of American Joint Committee on Cancer 
 
NX. Regional lymph nodes cannot be assessed  
N0. No regional lymph node metastasis  
N1. Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension  
N2. Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm 
in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in 
greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in 
greatest dimension  
N2a. Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 
6 cm in greatest dimension  
N2b. Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest 
dimension  
N2c. Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in 
greatest dimension  
N3. Metastasis in a lymph node more than 6 cm in greatest dimension 
Table 2. Definition of cutaneous squamous cell carcinoma Nodes (N) staging system in 7th 
edition of American Joint Committee on Cancer 
2.3 Factors related to prognosis 
2.3.1 Clinical 
The clinical factors classically related to prognosis are the tumor size and regional lymph 
node status (TNM stage). Many studies have confirmed both tumor size our local infiltration 
and presence and number of lymph node metastasis as the main prognosticator for 
advanced disease. The incidence of lymph node metastasis varys according the population 
studied from 4.5 to 17%(North, Spellman et al. 1997; Cherpelis, Marcusen et al. 2002; Mullen, 
Feng et al. 2006). Other factors have being pointed but the association is uncertain as 
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anatomic location and previous chronic disease locally on the skin (i.e. Marjolin ulcer). 
(Collins, Nickoonahand et al. 2004) 
2.3.2 Pathological 
A detailed histopathological descriptive classification considering all subtypes of squamous 
cell carcinoma of the skin was proposed by Cassarino (Cassarino, Derienzo et al. 2006), 
categorized tumors as low, intermediated and high risk, but it was not confirmed by well 
designed studies. The tumor length in millimeters (Breslow measurement) is associated with 
prognosis in some studies, but not confirmed(Breuninger, Black et al. 1990). The tumor 
grade, proposed by Broders and simplified to grade I, II and III (I well differentiated and III 
undifferentiated) is other controversial factor related to the prognosis, as well as the mitotic 
index and the Intratumoral lymphocytic infiltrate (ILI). In our retrospective study, the tumor 
grade was related to prognosis and the ILI was related to the lymph node metastasis.(de 
Lima Vazquez , Scapulatempo et al. 2011) 
2.3.3 Molecular 
With the advent of the molecular diagnosis, some authors looked at the relation of 
molecular changes and disease progression. Knowledge of the role of molecular markers 
in tumor progression and metastasis is limited. The tyrosine kinases Human Epidermal 
Receptor (HER) family (EGFR - Epidermal Growth Factor Receptor, HER-2, HER-3 and 
HER-4) are transmembrane glycoproteins related to cell proliferation, differentiation and 
apoptosis. Altered expression of the HER family is associated with several epithelial 
tumors such as breast carcinoma and esophageal squamous cell carcinoma. Small studies 
have also shown altered HER expression in localized squamous cell carcinoma when 
compared to normal skin. HER 2 expression in advanced CSCC of the trunk and 
extremities is not well studied and may be related to prognosis allowing the use of target 
therapies that block the HER pathway(Krahn, Leiter et al. 2001). E-cadherin is a 
transmembrane glycoprotein and it is a mediator of calcium-dependent cell-cell adhesion 
in normal cells. Reduced cell-cell adhesiveness is considered important in both early and 
late carcinogenis. High E-cadherin expression in cell cytoplasm and low expression in the 
cell membrane is associated with tumor aggressiveness in different cancers.(Koseki, Aoki 
et al. 1999) Podoplanin is a membrane protein found on lymphatic vessel endothelium. Its 
function is poorly understood although it may govern endothelial motility and its absence 
in animal studies is associated with lymphedema and malformation of lymphatic 
vessels.(Schacht, Ramirez et al. 2003) 
In our study with 55 patients with advanced cutaneous squamous cell carcinoma (CSCC) of 
the trunk and extremities, Primary tumor positivity was 25.5% for EGFR, 87.3% for HER-3 
and 48.1% for HER-4. Metastases were positive for EGFR in 41.7%, for HER-3 in 83.3% and 
HER-4 in 43.5%. HER-2 was negative in all samples. Membrane E-cadherin and cytoplasmic 
E-cadherin were positive in 47.3% and 30.2% of primary tumors and 45.5%and 27.3% of 
metastases respectively. Podoplanin was positive in 41.8% of primary tumors and 41.7% of 
metastases. The hiperexpression of Podoplanin in the primary tumor was related to lower 
survival rates. The HER family and the E-cadherin were not related to prognosis. The HER-4 
hiperexpression in the lymph node metastasis was associated to lower survival and showed 
that the HER family may play a role in the disease progression.(de Lima Vazquez , 
Scapulatempo et al. 2011) 
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2.4 The treatment modalities 
2.4.1 Surgery 
Surgery is the classic treatment for skin cancers and for advanced tumors it is still the most 
effective treatment. Unfortunately, in advanced cases amputations and extensive resections 
and dissections (i.e. extensive lymph node dissection with skin resection) are usual and have 
a high morbidity and sometimes mortality rate. Complex reconstructions with surgical flaps 
(figure 1) and other advanced techniques may be applied but local and clinical suboptimal 
conditions contraindicate them frequently. Local control is the goal, and the main objectives 
are to obtain clear margins and in case of lymph node metastasis, to clear completely the 
lymphatic chain (i.e. axilla or groin). Due the tumor characteristics of local and regional 
dissemination, aggressive approaches are indicated if clinical conditions are satisfactory. 
Recurrence rate vary in the literature achieving 50% {de Lima Vazquez, 2008}.  
2.4.2 Radiation therapy 
When surgery is not an option for advanced tumours, i.e – patient refusal, clinical adverse 
conditions - radiation may be applied, but with limited results. The main role of the 
radiation therapy is when incomplete resection occurs, and in the adjuvant setting, when 
tumour margins are not sufficient or after resection of bulky lymph node metastasis. 
Indications are personalised since there is no standard care with this method. 
3. Head and neck tumors 
3.1 Introduction 
Squamous cell carcinoma accounts for 20% of non-melanoma cancers of the head and neck 
(Alam and Ratner 2001). In most cases, these tumors are cured with surgical treatment and / 
or radiotherapy, but a small portion of these patients had unfavorable outcomes with high 
rates of metastases and regional recurrence after treatment, which is associated with 20% of 
deaths from skin cancer (Alam and Ratner 2001). This more aggressive presentation is found 
in patients referred for high risk, which the literature has discussed the factors involved in 
this group (Veness 2007). In head and neck surgery, it is particularly associated with the 
presence of regional metastasis and invasiveness of the primary tumor. The latest edition of 
the UICC AJCC, published in 2010 (Edge and Compton 2010), showed major changes in the 
staging of nonmelanoma skin cancers, remarking lymph node staging aligned with the other 
sites of head and neck and including new factors for classification of the primary tumor. 
This part of the chapter will present some specific features of the therapy of skin cancers of 
the head and neck that often overlap with those found in other regions of the body, but in 
advanced tumors may limit surgical treatment and carry a poor prognosis for these tumors. 
3.2 Advanced tumors: Characteristics of primary tumor  
The following factors define a high risk of metastasis and recurrence in skin cancers (Edge 
and Compton 2010): 
Size of the primary tumor greater than 2 cm 
Breslow tumor thickness greater than 2 mm, Clark level IV or greater 
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Fig. 1. A - Axilar lymphadenectomy with skin resection and miocutaneous flap prepared for 
the reconstruction. Fig. 1. B - Final aspect of the reconstruction  
A 
B 
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Perineural invasion (PNI) 
Poor differentiation 
Anatomic sites that which carry high risk for recurrence or metastasis  
Immunocompromised state of the patient 
These changes are based on data-derived, evidence-based medicine and some changed in 
the last edition of the AJCC and will be detailed below. 
Tumor size: this parameter does not present a linear correlation of increased risk of 
metastasis and recurrence, according to tumor growth, however a limit of 2 cm is shown in 
several articles as a risk factor for locoregional recurrence. In the sixth edition of the AJCC 
edition, the limit of 5 cm separated the tumors in T2 and T3, however this limit did not have 
enough evidence to be sustained and was abolished in the seventh edition, being replaced 
by parameters more related to the invasiveness than the diameter of tumor (Farasat, Yu et 
al. 2011). 
Tumor depth and PNI: Even the tumor thickness and depth of invasion are important risk 
factors to SCCHN metastasis and local recurrence (Farasat, Yu et al. 2011). So, in the last 
edition of AJCC, Breslow depth and Clark level were incorporated. These changes directly 
affected head and neck tumors that invade the facial bones or skull base, being classified as 
advanced tumors, with higher risk of metastases and local recurrence (Edge and Compton 
2010). 
Another factor was added is the perineural invasion of nerves at the base of the skull, which 
often restricts a craniofacial resection with clear margins and is associated with a worse 
prognosis. Although based on retrospective studies, PNI showed a higher association with 
tumors in the face, lower degree of differentiation, tumors larger than 2 cm and recurrent 
tumors (Leibovitch, Huilgol et al. 2005). There is evidence of an increased incidence of 
cervical lymphadenopathy and distant metastasis, along with significantly reduced survival 
in patients with tumors that showed PNI(Farasat, Yu et al. 2011). 
A careful radiological preoperative assessment may reveal tumor invasion of branches of 
the trigeminal or facial nerve. The use of CT and MRI in invasive tumors of the skull base 
shows high accuracy in detecting perineural invasions, when correlated with intraoperative 
and pathological findings (Gandhi, Panizza et al. 2010). 
Immunosuppression: Although not a specific factor that affects tumor staging, AJCC, in his 
last edition, highlights this as a risk factor for increased aggressiveness of skin tumors. 
Organ transplant recipients are 65 times greater risk of developing squamous cell carcinoma 
of the skin than the general population and have much more aggressive evolution.  
Location of primary tumor: some anatomical sites are more associated with worse outcomes 
in head and neck. This can be seen in sites that drain to the parotid gland like external ear, 
temple, forehead and anterior scalp. The lower lip also has an increased risk of nodal 
metastasis.(Veness 2007) 
Some series showed a poor outcome of cutaneous squamous cell carcinoma of external ear 
(Brantsch, Meisner et al. 2008; Turner, Morgan et al. 2009). Faustina et al found 24,3% of 
regional metastasis in 111 patients with squamous cell carcinoma of the eyelid and 
periocular region, advising close observation of parotid after the treatment of this 
site(Faustina, Diba et al. 2004) 
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Fig. 2. A (On the left): Clinical aspect of the patient with invasive skin tumor and bone 
exposure of the zigomatic arc with installed facial nerve paralysis. Fig. 2. B (right): The red 
arrow reveals perineural invasion of V3 and the blue arrow shows the skin tumor of 
temporal region. Fig. 2. C: Surgical aspect after removal of skin tumor, with sacrifice of the 
facial nerve, zigomatic arc, ascending mandible and parotid gland. The blue line delimits the 
temporal bone resection by the neurosurgical team and the instruments pointing V3 at skull 
base, with perineural invasion 
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Histopathological differentiation grade: tumors less differentiated are associated with a 
more aggressive outcome. This item also has changed in the last edition of the AJCC, 
becoming one of the high risk factors, opposed to being a separate classification as in the 
sixth edition. (Farasat, Yu et al. 2011) 
Lymph node metastases 
SCCHN that develop nodal metastasis in the parotid gland or the neck is an aggressive 
disease and show poor outcomes. Some studies these prognosis revealing 5-years overall 
survival rates from 22 to 36% (Khurana, Mentis et al. 1995; Kraus, Carew et al. 1998). 
Untill the sixth edition of AJCC, the nodal staging of squamous carcinoma of skin only 
separate the presence of nodal metastasis or no. This classification was pointed by several 
authors as insufficient, what have already indicated the need of a new proposal for lymph 
nodes staging, including a P stage for parotid metastasis and stratification of nodal disease 
(O'Brien, McNeil et al. 2002; Ch'ng, Maitra et al. 2006). The seventh edition of AJCC 
incorporated some changes in nodal classification aligning with the staging of lymph nodes 
from others sites of head and neck but the P staging has not been implemented, because of 
the benefit of having subgroups of P and N stage is uncertain, but further research may 
demonstrate the need of this staging system (Palme, MacKay et al. 2007; Forest, Clark et al. 
2010; O'Hara, Ferlito et al. 2010) 
In a survey of tertiary treatment centers, about 5% of squamous cell carcinomas present skin 
present metastasis, usually to regional lymph nodes of the parotid and cervical level II. (2, 
5). Sites such as cheek, ear, forehead, temple and lateral scalp are the most implicated in the 
onset of regional disease, which usually occurs on an average of 13 months of primary 
treatment, but may occur until 2 to 3 years later (Hong, Kriesel et al. 2005). The rate of 
regional metastases in head and neck can be between 10 and 20% when clinical and 
pathological characteristics of high-risk primary tumor are present. 
When parotid metastasis with clinical negative neck are present, the risk of occult 
metastases in the cervical lymph nodes reaches 35-50%, which justifies elective neck 
dissection in the presence of parotid involvement(O'Hara, Ferlito et al. 2010). The data by 
Vauterin revealed when positive pathological neck is observed, level II is involved in 79% of 
cases and external jugular chain lymph nodes are particularly at risk, what should have not 
be forgot to be included in the neck dissection. (Vauterin, Veness et al. 2006). 
Levels IV and V are only involved in massive lymph node disease to the neck, except in 
situations where the primary is located in the posterior scalp, in which the involvement of 
this code chain can be isolated. Metastases to the level I is present alone when the primary 
occurs in the anterior region of the face (O'Hara, Ferlito et al. 2010). 
The radiological search of metastases to the parotid and neck should be performed only in 
patients at high risk, which can use CT, MRI and USG-guided FNA (O'Hara, Ferlito et al. 
2010). 
The use of sentinel lymph node in squamous cell carcinoma in head and neck is not yet 
defined and is not routinely used in cancer not melanoma, due to the low risk of nodal 
metastasis, but has potential for improved survival in patients at high risk (O'Hara, Ferlito et 
al. 2010). The sentinel lymph node study in the parotid region should be done with caution 
because it adds a possible morbidity due to the risk of facial nerve injury. 
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3.3 Treatment 
3.3.1 Treatment of primary tumor 
The treatment of advanced SCCHN tumors usually involves surgical resection and adjuvant 
radiotherapy. The goal of surgical treatment is tumor resection with clear margins. Tumors 
that fail to be cleared surgically often recur despite radiation. In contrast, high-risk SCCHN 
with clear surgical margins has documented excellent outcomes when compared to those 
with unreported margin status (local recurrence 5% vs. 8%, nodal metastasis 5% vs. 14%, 
distant metastases 1% vs. 7%, and disease-specific death 1% vs. 7%). 
Skin squamous cell carcinoma with invasion of skull base are treated with craniofacial 
resections and have worse survival when compared to basal cell carcinomas. (Backous, 
DeMonte et al. 2005). Backous used as contraindication criteria for this type of resection 
encasement of the carotid artery or optic chiasm, cavernous sinus invasion or distant 
metastasis. Factors found to reduce survival are perineural invasion, intracranial extension 
with invasion of brain parenchyma and impossibility of adjuvant radiotherapy because of 
previous radiation. 
Immunosuppressed patients should receive more aggressive surgical treatment and 
adjuvant radiotherapy should be strongly considered. 
A multisciplinary aproach is recommended for the treatment of SCCHN, with combination 
of head and neck surgeon and plastic surgery, so that the reconstrution should not carry a 
limiting resection.  
3.3.2 Treatment of regional metastasis 
The published evidence suggests that the optimum treatment for metastatic SCCHN should 
be surgical resection with adjuvant radiotherapy. (O'Hara, Ferlito et al. 2010) 
The most common site of metastases in the head and neck is the parotid gland. Usually 
when performing parotidectomy is associated the dissection of cervical levels I-III in 
negative neck and a radical neck dissection in positive necks (14, 18). This treatment option 
can save adjuvant irradiation in the pathologically negative neck restricting the field of 
radiation only to the parotid field, but another option is the radiation of the clinically 
negative neck.  
In patients undergoing parotidectomy, Ebrahimi recommends selective neck dissection 
including level I to III for facial primaries, level II and III for anterior scalp and external ear 
primaries, and levels II to V for posterior scalp and neck primaries(Ebrahimi, Moncrieff et al. 
2010). Isolated metastases of level V and primary region of the scalp or posterior subocipital 
region, a posterior lateral neck dissection (II to V) is recommended. (O'Hara, Ferlito et al. 
2010) 
Cervical neck node disease without parotid involvement can be seen in 18 to 41% of 
patients.(Andruchow, Veness et al. 2006; Vauterin, Veness et al. 2006) In this situation, the 
recommendation is the treatment of the neck with classic or modified radical dissection 
associated with elective parotidectomy in primaries of anterior regions of scalp and lateral 
face (Barzilai, Greenberg et al. 2005; Jennings and Schmults 2010). 
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Fig. 3. A: Example of multidisciplinary aproach: recurrent squamous cell carcinoma after 
local excision and radiation therapy. Facial nerve paralysis and intratemporal perineural 
nerve spread. Fig. 3. B: Surgical field of total parotidectomy and sacrifice of the facial nerve 
and ascending portion of mandible and neck dissection of levels I-III with sacrifice of 
sternocleidomastoid muscle. The blue line delimits the temporal bone resection by the 
neurosurgical team, with frozen sections of the nerve stump.  
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Fig. 4. Surgical treatment aspect of a posterior scalp skin tumor with posterior lateral neck 
dissection ( cervical levels II-V), sparing the spinal acessory nerve 
Although some anatomical regions have an increased risk of developing regional 
metastases, it is difficult to recommend elective neck dissection as a routine base, because of 
the low rate of nodal spread and high prevalence of these skin cancers. Others risk factors 
should be added to consider elective regional treatment like immunnocompromised host, 
poorly diferentiated grade (Veness 2007). Elective parotidectomy for patients without 
clinical or radiological evidence of metastasis of the neck or parotid is not recommended by 
most authors (Osborne, Shaw et al. 2008). 
Intraparotid metastasis to lymph nodes may be attached to the facial nerve, which is at risk 
of sacrifice in some situations. All facial nerve not functioning in the preoperative evaluation 
or completely surrounded by tumor should be sacrificed but it should rarely be done when 
it has normal function before surgery. According to Iyer, surgical approaches to the parotid 
metastatic cancers shall, as far as possible, spare the facial nerve with normal function, even 
if that causes resection with microscopic involved margins and the need for adjuvant 
radiotherapy. Such strategie do not generate differences in the rates of recurrence and 
overall survival compared with patients undergoing resection with microscopically free 
margins. However, this study shows no statistical difference between groups, but shows a 
tendency to a worse local control and survival, which could have significance with a larger 
number of cases. In fact, free surgical margins greater than 5 mm are rarely obtained due to 
the proximity of parotidectomy metastasis with the facial nerve (Iyer, Clark et al. 2009). 
Parotidectomy may be associated with resection of skin tumors of the parotid region and the 
series of Lai reveals perineural invasion of the facial nerve in 6 of the 23. Lai recommends  
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Fig. 5. A: Squamous cell carcinoma of skin of parotid region, with in transit metastasis. Fig. 
5. B: Surgical field after ressection including superficial parotidectomy and the zigomatic arc 
with sacrifice of the superior branch of facial nerve that was involved by the tumor. 
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parotidectomy depending on the depth of the primary lesion, especially in the preauricular 
region. Similarly, facial nerve dissection is necessary in superficial parotidectomy for nodal 
involvement or deep invasion from preauricular primary lesions. As the facial nerve is 
identified, areas of gross tumor involvement may necessitate partial or total facial nerve 
resection. When there is sacrifice of the facial nerve, some authors recommend frozen 
sections of the facial nerve stumps, to ensure free margins before a microsurgical nerve 
reconstruction (Lai, Weinstein et al. 2002). 
3.3.3 Radiotherapy 
Primary radiation for SCCHN can be an alternative treatment when the surgucal defect 
causes challenging reconstructions and should be used in lesions with little invasiveness. 
Local tumor control in small lesions rivals that of surgical resection, even in recurrent 
disease. However, as T stage increases, local control decreases when compared to surgical 
excision.(Mendenhall, Amdur et al. 2009) 
The treatment of neck or parotid metastasis, surgery and adjuvant radiotherapy should be 
done rather than radiation alone(Palme, O'Brien et al. 2003). Multiple studies have noted 
decreased disease-specific survival in patients treated with RT alone (delCharco, 
Mendenhall et al. 1998; Veness, Palme et al. 2003) 
The use of adjuvant radiation should be strongly considered in incomplete excision or positive 
margins, perineural invasion, multiple nodal involvement and recurrent tumors. (Veness 2007) 
4. Systemic therapy (for all tumors) 
4.1 Adjuvant therapy for high risk SCCS 
The risk of locoregional recurrence and regional or distant metastasis is the most important 
factor in determining the treatment for cutaneous SCC. In a large review of studies of SCC 
of the skin, lip and ear, between 1940 and 1992 it was observed that recurrence rates double 
from 7.4% to 15.2% for tumors greater than 2 cm in diameter, and that tumors less than 4 
mm in depth are at low risk for metastasis compared with tumors deeper than 4 mm (6.7% 
and 45.7%, respectively). (Rowe, Carroll et al. 1992) Also, 30% of locally recurrent SCCS 
develop metastases. Long-term prognosis for metastatic disease is extremely poor. Ten-year 
survival rates are less than 20% for patients with regional lymph node involvement and less 
than 10% for patients with distant metastases. (Cherpelis, Marcusen et al. 2002). 
Histopathologic features associated with an increased risk of local failure or metastasis 
include large lesion size, perineural invasion, and involvement beyond the subcutaneous 
tissue. (Clayman, Lee et al. 2005)] 
Chemotherapy in the management of high-risk SCCS remains relatively unexplored. 
(Jennings and Schmults 2010) The role of retinoids, which are known to decrease new cancer 
formation, but do not alter the course of an existing tumor, as prophylactic agents in 
patients with diffuse actinic damage or recurrent CSCCs is well established, especially in 
organ transplant recipients (OTRs). (Harwood, Leedham-Green et al. 2005) Unfortunately, 
randomized trials of retinoids, either used alone for the adjuvant-treatment of established 
mucosal SCC of the head and neck (Toma, Bonelli et al. 2004) or in combination with 
interferon (Brewster, Lee et al. 2007) for established SCCS, have shown no benefit.  
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Many of the available agents with activity demonstrated in advanced SCCS, including EGRF 
inhibitors and oral capecitabine, are well tolerated with relatively low risks, and are 
potential candidates for adjuvant therapy in highest-risk cases. Further work remains to 
identify patient subsets likely to benefit from adjuvant chemotherapy and to define optimal 
regimens. Collaborative clinical trials are needed to establish standardized prognostic or 
treatment models to assist clinicians in most effectively identifying and managing patients 
at risk for poor outcomes. (LeBoeuf and Schmults 2011)  
4.2 Systemic therapy for advanced SCCS 
The use of systemic therapy is limited to patients with distant metastases or locally 
advanced disease that cannot be adequately managed with surgery or radiotherapy. 
Because of the rarity of metastatic squamous cell cancers of the skin, the approach to 
systemic treatment is based primarily upon isolated case reports, with only a few small case 
series. 
Treatment of metastatic SCC may include systemic chemotherapy or treatment with biologic 
response modifiers. The efficacy of these methods has not been established.  
Wollina and colleagues (Wollina, Hansel et al. 2005) reported 4 patients with advanced SCC 
of the skin who were treated with oral capecitabine and IFN subcutaneously, resulting in 
complete remission in 2 patients and partial response in the other 2. IFN may act 
synergistically to capecitabine by causing a forced accumulation of 5-FU in tumor cells as a 
result of stimulation of dThdPase. In another report the use of oral capecitabine alone for the 
treatment of 14 patients with advanced cutaneous SCC resulted in 2 partial remissions and 3 
minimal remissions. (Cartei, Cartei et al. 2000) 
Cisplatin-based combinations appear to be the most active regimens in the published 
experience. Most regimens that have been studied for the treatment of advanced SCCS were 
adapted from those used for squamous cell cancers arising in other sites. Sadek et al. 
reported on the treatment of 14 patients with advanced squamous cell carcinoma of the skin 
or lip with a combination of bolus cisplatin, plus a five-day infusion of bleomycin and 5-
fluorouracil. (Sadek, Azli et al. 1990) Four complete and seven partial responses were 
observed and in seven patients, tumor regression permitted subsequent definitive local 
treatment with either surgery or radiation therapy.  
Using a combination of cisplatin daily times four plus a four day continuous infusion of 
bleomycin to treat five patients with locally advanced disease of the head and neck (three 
squamous cell and two basal cell), Denic observed one complete response and 3 partial 
responses. (Denic 1999) One patient had disease progression. 
Multiple targeted therapies are being developed for many malignancies, including those 
with squamous cell histologies. These may ultimately have utility in patients with advanced 
or metastatic non melanoma skin cancers. The primary targets of molecular inhibition in 
squamous cell carcinoma include the epidermal growth factor receptor (EGFR), the vascular 
endothelial growth factor (VEGF) and its receptor, and tyrosine kinase (TK). (O'Bryan and 
Ratner 2011) Molecular studies have demonstrated that these molecules are overexpressed 
in a subset of SCCS and may be associated with more aggressive clinical behavior. (Detmar, 
Velasco et al. 2000; Maubec, Duvillard et al. 2005; Ch'ng, Low et al. 2008) 
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Intracellular signal transduction mediated by the epidermal growth factor receptor (EGFR) 
has been one of the most studied pathways in carcinogenesis. The phosphorylation of EGFR 
activates multiple biological processes, including apoptosis, differentiation, cellular 
proliferation, motility, invasion, adhesion, DNA repair, and survival. EGFR is a 
transmembrane tyrosine kinase receptor involved in the proliferation and survival of many 
cancer cells and is one of the first molecular target against which monoclonal antibodies 
have been developed for cancer therapy. EGFR plays an important role in tumorigenesis of 
non melanoma skin cancer, especially metastatic squamous cell carcinoma, via mechanisms 
similar to those of other visceral tumors. (Khan, Alam et al. 2011) 
Several case reports suggest that Cetuximab, a monoclonal antibody that targets the 
epidermal growth factor receptor (EGFR), has antitumor activity in patients with advanced 
squamous cell carcinoma of the skin. (Bauman, Eaton et al. 2007; Suen, Bressler et al. 2007; 
Arnold, Bruckner-Tuderman et al. 2009) 
Maubec and colleagues reported the results of a phase II study that included 36 patients 
with advanced squamous cell carcinoma of the skin treated with cetuximab in the first line 
setting. (Maubec, Duvillard et al. 2010) In this study, cetuximab was administered on a 
weekly schedule (400 mg/m2 on week 1 and then 250 mg/m2 weekly). Eight partial and 
two complete responses were observed, and 21 had stable disease for an overall disease 
control rate of 69 percent. Furthermore, three patients were able to undergo complete 
resection of their tumor following systemic treatment with cetuximab. Similarly to what is 
reported in other malignancies, patients developing acneiform rash apparently had a better 
outcome.  
The combination of cetuximab with chemotherapy is a promising approach. Association 
with platinum-based chemotherapy and 5-FU in patients with recurrent or metastatic SCC 
of the head and neck (SCCHN) has shown benefit in a large prospective randomized trial. 
(Vermorken, Mesia et al. 2008) In this study, 442 eligible patients with untreated recurrent or 
metastatic SCCHN were randomized to receive 5-FU with cisplatin or carboplatin, with or 
without cetuximab. The ORR was 36% versus 20% with and without cetuximab (P = 0.001). 
Survival increased from 7.4 to 10.1 months with the addition of cetuximab (P = 0.04), and 
progression-free survival increased from 3.3 to 5.6 months (P≤ 0.0001). 
Other targeted EGFR inhibitors are also currently under investigation in clinical trials 
mainly for the treatment of SCCHN, including Panitumumab (Vectibix, Amgen, Thousand 
Oaks, CA) which is a fully human monoclonal antibody to EGFR. (Lacouture and Melosky 
2007; AMGEN 2011; AMGEN 2011)  
Additionally, many targeted molecular therapies to VEGF and VEGF TKs have proven 
efficacy in other malignancies. Research into their use for SCCHN is growing and these 
agents may also be useful for the treatment of SCCS. (Wang and Agulnik 2008) 
Bevacicumab (Avastin, Genentech, South San Francisco, CA) is a fully human monoclonal 
antibody against VEGF, and is being tested for recurrent and metastatic SCCHN in a 
phase 3 trial comparing chemotherapy alone versus chemotherapy plus bevacizumab. 
(Wang and Agulnik 2008) There is hope that the combination of EGFR and VEGF pathway 
inhibitors will provide an increased clinical benefit in such patients. This alternative is 
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being studied in an ongoing phase 2 trial, cituximab, radiotherapy, and pemetrexed with 
or without bevacizumab is being tested in patients with locally advanced SCCHN. (Gold, 
Lee et al. 2009) 
As mentioned earlier, the vast majority of studies focus on the use of molecular inhibitors in 
SCCHN. More research is needed, for the development of new treatment modalities and to 
establish their role in treating patients with advanced or aggressive CSCC. 
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